• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

绘制T细胞活化蛋白表面V结构域免疫球蛋白抑制因子上的结合热点和瞬时结合口袋。

Mapping the Binding Hotspots and Transient Binding Pockets on V-Domain Immunoglobulin Suppressor of T Cell Activation Protein Surface.

作者信息

Li Bingjie, Xu Lixiu, Chen Chu, Ye Jiqing

机构信息

School of Pharmacy, Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Medical University, Hefei 230032, China.

出版信息

ACS Omega. 2024 Nov 23;9(49):48657-48669. doi: 10.1021/acsomega.4c07757. eCollection 2024 Dec 10.

DOI:10.1021/acsomega.4c07757
PMID:39676951
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11635502/
Abstract

V-domain immunoglobulin suppressor of T cell activation (VISTA), an inhibitory immune checkpoint present on both immune and tumor cells, has emerged as a highly promising target for cancer therapy due to its potential to overcome resistance encountered with existing immune checkpoint treatments. VSIG-3 is determined as an inhibitory ligand for VISTA, leading to the suppression of T cell proliferation. However, hotspots between VISTA/VSIG-3 protein-protein interaction remain ambiguous, mainly attributed to the lack of the structure of the VISTA/VSIG-3 complex. Therefore, in this study, in order to determine the energetic contributions of the interfacial residues on VISTA, we first constructed VISTA/VSIG-3 complex models by the protein docking method, followed by molecular dynamics simulations, binding free-energy decomposition, and alanine scanning. Results suggested that the putative hotspots in VISTA comprise residues His32, Tyr37, Thr35, Glu47, Val48, Gln49, Glu53, Arg54, Gln73, His122, and His126. Moreover, the distribution of the hotspots was clustered into two regions (hot regions I and II), and by using the TRAPP tool, transient subpockets within the hot regions were identified. Furthermore, conformational states of the binding pockets exhibiting druggability scores higher than those observed in the crystal structure were found. Overall, we hope that the findings outlined in this study can be used to facilitate the development of inhibitors targeting the VISTA/VSIG-3 immune checkpoint pathway in the future.

摘要

T细胞活化V结构域免疫球蛋白抑制因子(VISTA)是一种存在于免疫细胞和肿瘤细胞上的抑制性免疫检查点,由于其有潜力克服现有免疫检查点治疗中遇到的耐药性,已成为癌症治疗中极具前景的靶点。VSIG-3被确定为VISTA的抑制性配体,可导致T细胞增殖受到抑制。然而,VISTA/VSIG-3蛋白-蛋白相互作用的热点仍不明确,主要原因是缺乏VISTA/VSIG-3复合物的结构。因此,在本研究中,为了确定VISTA上界面残基的能量贡献,我们首先通过蛋白质对接方法构建了VISTA/VSIG-3复合物模型,随后进行分子动力学模拟、结合自由能分解和丙氨酸扫描。结果表明,VISTA中假定的热点包括His32、Tyr37、Thr35、Glu47、Val48、Gln49、Glu53、Arg54、Gln73、His122和His126等残基。此外,这些热点分布聚集成两个区域(热点区域I和II),并使用TRAPP工具在热点区域内识别出瞬时亚口袋。此外,还发现了结合口袋的构象状态,其可成药分数高于晶体结构中的观察值。总体而言,我们希望本研究中概述的发现可用于促进未来针对VISTA/VSIG-3免疫检查点途径的抑制剂的开发。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9628/11635502/78793c1c9a07/ao4c07757_0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9628/11635502/dc79f465d333/ao4c07757_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9628/11635502/5cd0dfdb81c1/ao4c07757_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9628/11635502/e65da05c6961/ao4c07757_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9628/11635502/7337d35c5f9e/ao4c07757_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9628/11635502/36c8e8b486f5/ao4c07757_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9628/11635502/4fbe51c4e2cb/ao4c07757_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9628/11635502/cd9e8ab757fe/ao4c07757_0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9628/11635502/4c7a3d0a9543/ao4c07757_0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9628/11635502/053a0410a848/ao4c07757_0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9628/11635502/78793c1c9a07/ao4c07757_0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9628/11635502/dc79f465d333/ao4c07757_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9628/11635502/5cd0dfdb81c1/ao4c07757_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9628/11635502/e65da05c6961/ao4c07757_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9628/11635502/7337d35c5f9e/ao4c07757_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9628/11635502/36c8e8b486f5/ao4c07757_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9628/11635502/4fbe51c4e2cb/ao4c07757_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9628/11635502/cd9e8ab757fe/ao4c07757_0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9628/11635502/4c7a3d0a9543/ao4c07757_0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9628/11635502/053a0410a848/ao4c07757_0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9628/11635502/78793c1c9a07/ao4c07757_0010.jpg

相似文献

1
Mapping the Binding Hotspots and Transient Binding Pockets on V-Domain Immunoglobulin Suppressor of T Cell Activation Protein Surface.绘制T细胞活化蛋白表面V结构域免疫球蛋白抑制因子上的结合热点和瞬时结合口袋。
ACS Omega. 2024 Nov 23;9(49):48657-48669. doi: 10.1021/acsomega.4c07757. eCollection 2024 Dec 10.
2
A small molecule inhibitor of VSIG-8 prevents its binding to VISTA.一种 VSIG-8 的小分子抑制剂可阻止其与 VISTA 的结合。
Invest New Drugs. 2022 Aug;40(4):690-699. doi: 10.1007/s10637-022-01244-4. Epub 2022 Apr 11.
3
VSIG-3 as a ligand of VISTA inhibits human T-cell function.VSIG-3 作为 VISTA 的配体抑制了人 T 细胞的功能。
Immunology. 2019 Jan;156(1):74-85. doi: 10.1111/imm.13001. Epub 2018 Oct 10.
4
VISTA and its ligands: the next generation of promising therapeutic targets in immunotherapy.VISTA及其配体:免疫疗法中新一代有前景的治疗靶点。
Cancer Cell Int. 2023 Nov 7;23(1):265. doi: 10.1186/s12935-023-03116-0.
5
Structural Basis of VSIG3: The Ligand for VISTA.VSIG3 的结构基础:VISTA 的配体。
Front Immunol. 2021 Mar 25;12:625808. doi: 10.3389/fimmu.2021.625808. eCollection 2021.
6
VSIG-3/IGSF11 silencing in A2058 melanoma cells simultaneously suppresses melanoma progression and induces anti-tumoral cytokine profile in human T cells: In silico and in vitro study.A2058黑色素瘤细胞中VSIG-3/IGSF11基因沉默同时抑制黑色素瘤进展并诱导人T细胞产生抗肿瘤细胞因子谱:计算机模拟和体外研究
Naunyn Schmiedebergs Arch Pharmacol. 2025 Apr;398(4):3861-3880. doi: 10.1007/s00210-024-03491-z. Epub 2024 Oct 4.
7
V-Set and immunoglobulin domain containing (VSIG) proteins as emerging immune checkpoint targets for cancer immunotherapy.V -set 及免疫球蛋白结构域包含蛋白(VSIG)作为癌症免疫治疗中的新兴免疫检查点靶点。
Front Immunol. 2022 Sep 15;13:938470. doi: 10.3389/fimmu.2022.938470. eCollection 2022.
8
VISTA Emerges as a Promising Target against Immune Evasion Mechanisms in Medulloblastoma.VISTA成为针对髓母细胞瘤免疫逃逸机制的一个有前景的靶点。
Cancers (Basel). 2024 Jul 24;16(15):2629. doi: 10.3390/cancers16152629.
9
Targeting the V-Type Immunoglobulin Domain-Containing Suppressor to T Cell Activation (VISTA) with Agonist Monoclonal Antibodies in Autoimmunity.用激动型单克隆抗体靶向 V 型免疫球蛋白域包含抑制 T 细胞激活(VISTA)治疗自身免疫病。
Crit Rev Immunol. 2022;42(4):37-49. doi: 10.1615/CritRevImmunol.2023047591.
10
Discovery of Novel Inhibitors From Medicinal Plants for V-Domain Ig Suppressor of T-Cell Activation.从药用植物中发现用于T细胞激活的V结构域Ig抑制因子的新型抑制剂。
Front Mol Biosci. 2021 Oct 26;8:716735. doi: 10.3389/fmolb.2021.716735. eCollection 2021.

引用本文的文献

1
[IGSF11: A Novel Target for Cancer Immunotherapy].[免疫球蛋白超家族成员11:癌症免疫治疗的新靶点]
Zhongguo Fei Ai Za Zhi. 2025 May 20;28(5):371-378. doi: 10.3779/j.issn.1009-3419.2025.106.14.

本文引用的文献

1
VISTA and its ligands: the next generation of promising therapeutic targets in immunotherapy.VISTA及其配体:免疫疗法中新一代有前景的治疗靶点。
Cancer Cell Int. 2023 Nov 7;23(1):265. doi: 10.1186/s12935-023-03116-0.
2
Development of Inhibitors Targeting the V-Domain Ig Suppressor of T Cell Activation Signal Pathway.靶向 T 细胞活化抑制信号通路 V 结构域免疫球蛋白的抑制剂的开发。
J Med Chem. 2022 Sep 22;65(18):11900-11912. doi: 10.1021/acs.jmedchem.2c00803. Epub 2022 Sep 9.
3
RING 3.0: fast generation of probabilistic residue interaction networks from structural ensembles.
RING 3.0:从结构集合中快速生成概率残基相互作用网络。
Nucleic Acids Res. 2022 Jul 5;50(W1):W651-W656. doi: 10.1093/nar/gkac365.
4
Traversing through the Dynamic Protein-Protein Interaction Landscape and Conformational Plasticity of PD-1 for Small-Molecule Discovery.穿越 PD-1 的动态蛋白质-蛋白质相互作用景观和构象可塑性,以发现小分子。
J Med Chem. 2022 Apr 28;65(8):5941-5953. doi: 10.1021/acs.jmedchem.2c00176. Epub 2022 Apr 14.
5
The immune checkpoint VISTA exhibits high expression levels in human gliomas and associates with a poor prognosis.免疫检查点 VISTA 在人类脑胶质瘤中高表达,并与不良预后相关。
Sci Rep. 2021 Nov 2;11(1):21504. doi: 10.1038/s41598-021-00835-0.
6
gmx_MMPBSA: A New Tool to Perform End-State Free Energy Calculations with GROMACS.gmx_MMPBSA:一种使用GROMACS进行终态自由能计算的新工具。
J Chem Theory Comput. 2021 Oct 12;17(10):6281-6291. doi: 10.1021/acs.jctc.1c00645. Epub 2021 Sep 29.
7
Amateur antigen-presenting cells in the tumor microenvironment.肿瘤微环境中的非专职抗原呈递细胞。
Mol Carcinog. 2022 Feb;61(2):153-164. doi: 10.1002/mc.23354. Epub 2021 Sep 27.
8
VISTA: A Promising Target for Cancer Immunotherapy?VISTA:癌症免疫疗法的一个有前景的靶点?
Immunotargets Ther. 2021 Jun 22;10:185-200. doi: 10.2147/ITT.S260429. eCollection 2021.
9
Structural Basis of VSIG3: The Ligand for VISTA.VSIG3 的结构基础:VISTA 的配体。
Front Immunol. 2021 Mar 25;12:625808. doi: 10.3389/fimmu.2021.625808. eCollection 2021.
10
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion.癌症中的抗原呈递:对肿瘤免疫原性和免疫逃逸的深入了解。
Nat Rev Cancer. 2021 May;21(5):298-312. doi: 10.1038/s41568-021-00339-z. Epub 2021 Mar 9.